Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233460 | 0.82 | CA2 (0.51) | CA2CA12CA1CA9CCR2 | |
| SCHEMBL18223712 | 0.82 | CA2 (0.51) | CA2CA12CA1CA9ATM | |
| SCHEMBL18223609 | 0.78 | TRPA1 (0.45) | CA2CA12CA1CA9CCR2 | |
| SCHEMBL6683885 | 0.76 | CYP2A6 (0.46) | CA2CCR2CHRM2CHRM4CHRM5 | |
| SCHEMBL16985241 | 0.76 | CA2 (0.67) | CA2CA12CA1CA9CCR2 | |
| SCHEMBL18233477 | 0.73 | TRPA1 (0.50) | CA2CA12CA1CA9CCR2 | |
| SCHEMBL18233472 | 0.73 | ATM (0.42) | CA2CA12CA1CA9ATM | |
| SCHEMBL20577822 | 0.73 | TRPA1 (0.50) | CA2CA12CA1CA9CCR2 | |
| SCHEMBL18233473 | 0.72 | CA2 (0.39) | CA2CA12CA1CA9ATM | |
| SCHEMBL18233471 | 0.72 | CA2 (0.42) | CA2CA12CA1CA9ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20180162844-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162844-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115507-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | 味の素株式会社 | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | CA2 210/4885CA12 2393/4885CA1 1394/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | CA2 210/4885CA12 2393/4885CA1 1394/4885 |
| US-20180162844-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | TRPA1, TRPV1, TRPV2 | CA2 834/4885CA12 4355/4885CA1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.